Cargando…

Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics

BACKGROUND: Gastrointestinal stromal tumours (GIST) are mainly characterised by the presence of activating mutations in either of the two receptor tyrosine kinases c-KIT or platelet-derived growth factor receptor-α (PDGFRα). Most mechanistic studies dealing with GIST mutations have focused on c-KIT...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahlawane, Christelle, Eulenfeld, René, Wiesinger, Monique Y, Wang, Jiali, Muller, Arnaud, Girod, Andreas, Nazarov, Petr V, Felsch, Kathrin, Vallar, Laurent, Sauter, Thomas, Satagopam, Venkata P, Haan, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396151/
https://www.ncbi.nlm.nih.gov/pubmed/25880691
http://dx.doi.org/10.1186/s12964-015-0096-8
_version_ 1782366553166053376
author Bahlawane, Christelle
Eulenfeld, René
Wiesinger, Monique Y
Wang, Jiali
Muller, Arnaud
Girod, Andreas
Nazarov, Petr V
Felsch, Kathrin
Vallar, Laurent
Sauter, Thomas
Satagopam, Venkata P
Haan, Serge
author_facet Bahlawane, Christelle
Eulenfeld, René
Wiesinger, Monique Y
Wang, Jiali
Muller, Arnaud
Girod, Andreas
Nazarov, Petr V
Felsch, Kathrin
Vallar, Laurent
Sauter, Thomas
Satagopam, Venkata P
Haan, Serge
author_sort Bahlawane, Christelle
collection PubMed
description BACKGROUND: Gastrointestinal stromal tumours (GIST) are mainly characterised by the presence of activating mutations in either of the two receptor tyrosine kinases c-KIT or platelet-derived growth factor receptor-α (PDGFRα). Most mechanistic studies dealing with GIST mutations have focused on c-KIT and far less is known about the signalling characteristics of the mutated PDGFRα proteins. Here, we study the signalling capacities and corresponding transcriptional responses of the different PDGFRα proteins under comparable genomic conditions. RESULTS: We demonstrate that the constitutive signalling via the oncogenic PDGFRα mutants favours a mislocalisation of the receptors and that this modifies the signalling characteristics of the mutated receptors. We show that signalling via the oncogenic PDGFRα mutants is not solely characterised by a constitutive activation of the conventional PDGFRα signalling pathways. In contrast to wild-type PDGFRα signal transduction, the activation of STAT factors (STAT1, STAT3 and STAT5) is an integral part of signalling mediated via mutated PDGF-receptors. Furthermore, this unconventional STAT activation by mutated PDGFRα is already initiated in the endoplasmic reticulum whereas the conventional signalling pathways rather require cell surface expression of the receptor. Finally, we demonstrate that the activation of STAT factors also translates into a biologic response as highlighted by the induction of STAT target genes. CONCLUSION: We show that the overall oncogenic response is the result of different signatures emanating from different cellular compartments. Furthermore, STAT mediated responses are an integral part of mutated PDGFRα signalling. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12964-015-0096-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4396151
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43961512015-04-14 Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics Bahlawane, Christelle Eulenfeld, René Wiesinger, Monique Y Wang, Jiali Muller, Arnaud Girod, Andreas Nazarov, Petr V Felsch, Kathrin Vallar, Laurent Sauter, Thomas Satagopam, Venkata P Haan, Serge Cell Commun Signal Research BACKGROUND: Gastrointestinal stromal tumours (GIST) are mainly characterised by the presence of activating mutations in either of the two receptor tyrosine kinases c-KIT or platelet-derived growth factor receptor-α (PDGFRα). Most mechanistic studies dealing with GIST mutations have focused on c-KIT and far less is known about the signalling characteristics of the mutated PDGFRα proteins. Here, we study the signalling capacities and corresponding transcriptional responses of the different PDGFRα proteins under comparable genomic conditions. RESULTS: We demonstrate that the constitutive signalling via the oncogenic PDGFRα mutants favours a mislocalisation of the receptors and that this modifies the signalling characteristics of the mutated receptors. We show that signalling via the oncogenic PDGFRα mutants is not solely characterised by a constitutive activation of the conventional PDGFRα signalling pathways. In contrast to wild-type PDGFRα signal transduction, the activation of STAT factors (STAT1, STAT3 and STAT5) is an integral part of signalling mediated via mutated PDGF-receptors. Furthermore, this unconventional STAT activation by mutated PDGFRα is already initiated in the endoplasmic reticulum whereas the conventional signalling pathways rather require cell surface expression of the receptor. Finally, we demonstrate that the activation of STAT factors also translates into a biologic response as highlighted by the induction of STAT target genes. CONCLUSION: We show that the overall oncogenic response is the result of different signatures emanating from different cellular compartments. Furthermore, STAT mediated responses are an integral part of mutated PDGFRα signalling. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12964-015-0096-8) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-31 /pmc/articles/PMC4396151/ /pubmed/25880691 http://dx.doi.org/10.1186/s12964-015-0096-8 Text en © Bahlawane et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bahlawane, Christelle
Eulenfeld, René
Wiesinger, Monique Y
Wang, Jiali
Muller, Arnaud
Girod, Andreas
Nazarov, Petr V
Felsch, Kathrin
Vallar, Laurent
Sauter, Thomas
Satagopam, Venkata P
Haan, Serge
Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics
title Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics
title_full Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics
title_fullStr Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics
title_full_unstemmed Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics
title_short Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics
title_sort constitutive activation of oncogenic pdgfrα-mutant proteins occurring in gist patients induces receptor mislocalisation and alters pdgfrα signalling characteristics
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396151/
https://www.ncbi.nlm.nih.gov/pubmed/25880691
http://dx.doi.org/10.1186/s12964-015-0096-8
work_keys_str_mv AT bahlawanechristelle constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics
AT eulenfeldrene constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics
AT wiesingermoniquey constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics
AT wangjiali constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics
AT mullerarnaud constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics
AT girodandreas constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics
AT nazarovpetrv constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics
AT felschkathrin constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics
AT vallarlaurent constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics
AT sauterthomas constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics
AT satagopamvenkatap constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics
AT haanserge constitutiveactivationofoncogenicpdgframutantproteinsoccurringingistpatientsinducesreceptormislocalisationandalterspdgfrasignallingcharacteristics